Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Novartis is laying off 139 employees in East Hanover, NJ, primarily affecting commercial field sales teams working on Xolair (allergy/asthma) and Tafinlar-Mekinist (cancer) treatments. The cuts, ...

FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New Jersey. Adragos Pharma acquires Baccinex. Gelteq plans gel solution ...

Recursion Pharmaceuticals laid off under 20% of staff following merger with Exscientia. Oxford Nanopore partners with UK Biobank for epigenetic dataset project. Portage Biotech continues strategic ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Idor­sia is mak­ing moves to stretch its cash re­serves fur­ther. The Swiss drug­mak­er said it is nar­row­ing its ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...